The 'Mojo' Weight Loss Injection: What It Actually Is

Step 1, Understanding what this injection actually is

The phrase 'mojo injection' is informal shorthand that circulates online and in gyms, but it doesn't correspond to a product name. What people mean, almost always, is one of the two GLP-1 medicines licensed in the UK for weight management: Mounjaro (tirzepatide, made by Eli Lilly) or Wegovy (semaglutide, made by Novo Nordisk). Both are once-weekly subcutaneous injections delivered via a pre-filled pen into the abdomen, thigh, or upper arm.

Tirzepatide works on two receptors (GLP-1 and GIP) that are involved in appetite signalling and blood-sugar regulation. Semaglutide targets GLP-1 alone. In both cases the effect is meaningful: appetite falls, gastric emptying slows, and most people find they feel full on noticeably less food. The NHS patient information for tirzepatide explains the mechanism in plain language and is a good starting point if you want the detail before your consultation.

It's worth knowing that Ozempic (another medicine people sometimes mention in the same breath) is also semaglutide, but licensed for type 2 diabetes, not weight loss. The distinction matters because eligibility criteria, dosing, and clinical monitoring differ. If you've seen Ozempic discussed in weight-loss contexts, this overview of licensed weight-loss injections clarifies what's actually available and what isn't.

Step 2, The clinical assessment that has to come first

These medicines are Prescription-Only for a reason. Before any pen is dispensed, a prescriber reviews your medical history, your current weight, any conditions you have, and any other medicines you take. That's not a formality, it's where contraindications get caught and dosing decisions get made.

At nume (sorry, at nume) the consultation is reviewed the same day by a GPhC-registered Independent Prescriber. A real clinician reads your answers; no automated decision-making determines approval. Identity is confirmed with photo ID, and weight is checked live on video. If you're transferring from another provider and want to continue at a higher dose, evidence of your current treatment is required before that dose is approved.

Eligibility broadly follows the licensed criteria: adults with a BMI of 30 or above, or a BMI of 27 or above alongside a weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, or obstructive sleep apnoea. BMI alone doesn't guarantee a prescription; the prescriber looks at the full picture. If you're unsure where you stand, the free consultation is the place to find out.

Step 3, What the injection schedule looks like in practice

Once a prescription is issued, treatment begins at a low starter dose designed to let your body adjust before moving upward. For tirzepatide that's 2.5 mg; for semaglutide it's 0.25 mg. The prescriber typically increases the dose in four-week steps, and neither medicine jumps straight to its maximum maintenance dose on day one.

Each pen contains four weekly doses. You inject once a week on the same day if possible, rotating between injection sites to reduce irritation. Preparation is simple: let the pen come to room temperature, choose a clean site, and use a fresh needle each time. Correct technique matters more than people expect, and if you want a full walkthrough of how to use an m injection for weight loss correctly, that guide covers everything from site rotation to what to do if you miss a dose. If you need to travel with your medication, the relevant section of our weight-loss injections guide covers storage and travel practicalities.

Side effects are most common in the first few weeks and after each dose increase. Nausea, loose stools, constipation, reflux, and fatigue are the ones people report most often; for most they settle within a week or two. On 29 January 2026 the MHRA issued a Drug Safety Update for GLP-1 medicines specifically highlighting acute pancreatitis: if you develop severe, persistent stomach pain that reaches the back (with or without vomiting) seek urgent medical attention. The Yellow Card scheme is the official route for reporting any suspected side effects during your treatment.

Step 4, What results to expect, and the honest caveats

Clinical trial results for these medicines are among the strongest seen for any pharmaceutical weight-management treatment. In SURMOUNT-1 (tirzepatide, 72 weeks, thousands of adults with obesity), participants on the highest dose lost an average of around 20–21% of body weight. The STEP 1 trial of semaglutide 2.4 mg over 68 weeks showed an average reduction of roughly 15%. Both trials were conducted alongside a reduced-calorie diet and increased physical activity, conditions the medicines are licensed to complement, not replace.

Real-world results vary. Some people lose considerably more; others less. If you are weighing up which option suits you, reading about the mon weight loss injection alongside the semaglutide options can help you and your prescriber reach a more informed decision together. The medicines work best alongside sustainable changes to eating and movement, and a prescriber or dietitian is the right person to help you shape those. On the cost side, a straightforward breakdown of what weight-loss injection treatment costs in the UK sets out what's typically included in a legitimate private prescription, which is useful context before you start comparing providers.

People sometimes feel nervous about self-injecting for the first time. That's entirely understandable, most of our prescribers hear it regularly. In practice, the pens are designed to be as simple as possible, and the first injection is almost always less daunting than anticipated. Many patients also find it helpful to read through real experiences of weight loss injection r before they begin, as seeing how others have managed the process can make starting feel far less intimidating. If you have specific technique questions, our FAQs cover the practical detail, or you can reach us directly through our support team, available seven days a week.